CAC Software vs Lung Density Analysis
AI Verdict
Choose CAC Software if…
Choose CAC Software if your primary objective is to assess a patient's risk for coronary artery disease by quantifying calcification in the coronary arteries. This tool is ideal for radiologists and cardiologists needing automated Agatston scores and 3D visualizations from non-contrast chest CT scans to support cardiovascular risk stratification.
View CAC Software →Choose Lung Density Analysis if…
Choose Lung Density Analysis if you need comprehensive quantitative analysis and 3D visualization of lung conditions such as COPD, emphysema, or air-trapping. This software is particularly useful for pulmonologists and radiologists managing patients with chronic lung diseases or those undergoing lung cancer screening, providing detailed reports for diagnosis and personalized care.
View Lung Density Analysis →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | CAC Software | Lung Density Analysis |
|---|---|---|
| Deployment | Cloud-based (SaaS), integrates with PACS | Unknown |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Lung Density AnalysisBoth tools are designed for fully automated integration into existing PACS/DICOM workflows, minimizing user intervention. However, Tool B explicitly mentions 'stand-alone web-based' access and a 'Patient-centered LungMapu2122 report' for smoking cessation counseling, which enhances accessibility and patient communication, giving it a slight edge in overall usability.
Clinical Value
Lung Density AnalysisWhile Tool A provides valuable coronary artery calcification quantification for CAD risk assessment, Tool B offers a more comprehensive and nuanced analysis for multiple complex lung conditions like COPD, emphysema, asthma, and BOS. Its validation for low-dose CT in lung cancer screening, functional mapping capabilities, and support for surgical planning and patient counseling demonstrate a broader and deeper clinical utility.
Pricing & Value
TieBoth tools are from the same vendor, Imbio, and explicitly state 'contact for pricing' with no publicly disclosed pricing details. Without specific pricing information for either product, a direct comparison of their pricing and overall value is not possible.
Enterprise Readiness
Lung Density AnalysisBoth tools are FDA cleared, HIPAA compliant, and offer BAAs, demonstrating strong foundational enterprise readiness. Tool B, however, lists a slightly broader range of deployment options, including 'Locally virtualized (VM, Docker)' and 'AI marketplace/distribution platforms', in addition to cloud and on-premise, offering greater flexibility for diverse enterprise IT environments.
Innovation
Lung Density AnalysisBoth tools leverage AI/deep learning, but Tool B explicitly highlights unique technological advancements such as 'Imbio Noise Reduction Technology (NRT)' for low-dose scans and 'Patented Parametric Response Mapping (PRM) technology' for functional lung mapping. These specific features indicate more distinct innovation in its domain compared to the general deep-learning application for CAC in Tool A.
Support & Docs
TieAs both products are from Imbio, they benefit from the same corporate-level support infrastructure. Imbio offers 24/7/365 customer support via phone and email, and provides product documentation, such as user manuals, upon request. There is no specific differentiator in support or documentation mentioned for either tool.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | CAC Software | Lung Density Analysis |
|---|---|---|
| Product Name | CAC Software | Lung Density Analysis |
| Primary Function | Automated image post-processing algorithms to determine location and calculate amount of calcification within coronary arteries. | AI-driven medical imaging software providing quantitative analysis and 3D visualization of lung conditions from CT scans. |
| Target Specialties | Cardiology, Radiology | Pulmonology, Radiology |
| Key Output/Analysis Focus | Quantification of calcification within coronary arteries. | Automated detection, visualization, and quantification of emphysema; mapping of normal lung, air-trapping, and emphysema (Functional LDA); advanced density analysis for COPD, Asthma, BOS. |
| Specific Metrics Provided | Agatston score, arterial age, calcified lesion mass and volume. | Not specified |
| Input Scan Type | Non-contrast, chest computed tomography (CT). | CT scans, validated for low-dose CT scans in lung cancer screening. |
| Reporting/Visualization | 3D visualizations and annotated images. | Patient-centered LungMapu2122 report for smoking cessation counseling; fully automated quantitative analysis and 3D visualization to PACS; quantitative reports with coronal, axial, sagittal visuals and bar charts. |
Videos
Demos, reviews, and walkthroughs featuring CAC Software and Lung Density Analysis.